TEL AVIV, Israel, Nov. 5, 2018 /PRNewswire/ -- Cellect
Biotechnology Ltd. (Nasdaq: APOP), a developer of novel stem
cell production technology, announced today that it has received a
formal Notice of Allowance from the Japanese and Australian Offices
for Patents & Trademarks (Japanese Application No. 2014-560516;
Australian Application No. 20132s29008) covering a key composition
of matter and method of use of Cellect's ApoGraft technology in
devices for stem cell selection.
The current patent significantly enhances Cellect's protection
of its core technology and its commercial applications by covering
the various devices using the ApoGraft for a positive selection of
stem cells.
The device can enable cell selection in a simplified and
affordable setting using an off-the-shelf product - a solution that
currently does not exist and potentially covering a wide range of
unmet medical needs. Furthermore, it brings a first in kind method
for obtaining of raw material (specific cell types) for many of the
cell therapeutics and therefore is anticipated to take a pivotal
role in the fast growing cell therapy market.
"Japan and Australia are among the most advanced
healthcare systems in the world especially for cell therapies and
very important markets. As country regulators are fast-tracking
stem cell therapies, we see partnering opportunities with Japanese
and Australian healthcare sector companies and researchers.
Combined with recent clinical and product developments, we believe
this will position Cellect to meet the needs of the
ever-growing Cell Therapy Industry. Working with partners to
improve the safety and efficacy of stem cells and expanding
regenerative medicine's wide scale availability and affordability
are cornerstones of Cellect's strategy. Our growing IP estate
supports this purpose," stated Cellect CBO, Andrew Sabatier.
The devices covered by the patent are essentially containers (a
bag, column, tube, bottle, vial or flask) comprised of a
biocompatible material and a biologically active cell surface
apoptosis-inducing ligand immobilized to a surface that is adapted
for cell selection by elimination of apoptosis-sensitive cells.
Specifically, the patent protects the company's planned devices and
any devices planned by other companies adapted for selection of
cells that are resistant to receptor-mediated apoptosis and a
method for using the device.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a
breakthrough technology for the selection of stem cells from any
given tissue that aims to improve a variety of stem cell-based
therapies.
The Company's technology is expected to provide research,
hospitals and pharma companies with the tools to rapidly isolate
stem cells in quantity and quality allowing stem cell-based
treatments and procedures in a wide variety of applications in
regenerative medicine. The Company's current clinical trial is
aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss our expectations regarding the role that the
Company's technology will play in the future and the protection
that the patent may provide. These forward-looking statements
and their implications are based on the current expectations of the
management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
In addition, historical results or conclusions from scientific
research and clinical studies do not guarantee that future results
would suggest similar conclusions or that historical results
referred to herein would be interpreted similarly in light of
additional research or otherwise. The following factors, among
others, could cause actual results to differ materially from those
described in the forward-looking statements: the Company's history
of losses and needs for additional capital to fund its operations
and its inability to obtain additional capital on acceptable terms,
or at all; the Company's ability to continue as a going concern;
uncertainties of cash flows and inability to meet working capital
needs; the Company's ability to obtain regulatory approvals; the
Company's ability to obtain favorable pre-clinical and clinical
trial results; the Company's technology may not be validated and
its methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products.. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in the Company's Annual Report on Form
20-F for the fiscal year ended December 31,
2017 filed with the U.S. Securities and Exchange Commission
("SEC"), which is available on the SEC's website,
http://www.sec.gov, and in the Company's periodic filings with the
SEC.
Contact:
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
http://www.cellect.co
+972-9-974-1444
View original
content:http://www.prnewswire.com/news-releases/cellect-receives-multiple-patent-grants-300743723.html
SOURCE Cellect Biotechnology Ltd.